Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study | Zendy

Jessica Cusato | Zendy; Amedeo De Nicolò | Zendy; Lucio Boglione | Zendy; F. Favata | Zendy; Alessandra Ariaudo | Zendy; Simone Mornese Pinna | Zendy; Chiara Carcieri | Zendy; Federica Guido | Zendy; Valeria Avataneo | Zendy; Giuseppe Cariti | Zendy; Giovanni Di Perri | Zendy; Antonio D’Avolio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study

Author(s) -

Jessica Cusato,

Amedeo De Nicolò,

Lucio Boglione,

F. Favata,

Alessandra Ariaudo,

Simone Mornese Pinna,

Chiara Carcieri,

Federica Guido,

Valeria Avataneo,

Giuseppe Cariti,

Giovanni Di Perri,

Antonio D’Avolio

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky053

Subject(s) - sofosbuvir , pharmacogenetics , medicine , drug , pharmacology , virology , ribavirin , genotype , hepatitis c virus , biology , virus , genetics , gene

Sofosbuvir is a potent nucleotide HCV NS5B polymerase inhibitor that is also a P-glycoprotein (encoded by the ABCB1 gene) and breast cancer resistance protein (encoded by the ABCG2 gene) substrate. Concerning previous anti-HCV therapies, pharmacogenetics had a significant impact, particularly considering the association of interleukin28B polymorphisms with dual-therapy (ribavirin + pegylated IFN) outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research